Rizatriptan benzoat
Rizatriptan benzoat Brand names, Rizatriptan benzoat Analogs
Rizatriptan benzoat Brand Names Mixture
- No information avaliable
Rizatriptan benzoat Chemical_Formula
C15H19N5
Rizatriptan benzoat RX_link
http://www.rxlist.com/cgi/generic2/rizatrip.htm
Rizatriptan benzoat fda sheet
Rizatriptan benzoat msds (material safety sheet)
Rizatriptan benzoat Synthesis Reference
No information avaliable
Rizatriptan benzoat Molecular Weight
269.345 g/mol
Rizatriptan benzoat Melting Point
178-180 oC
Rizatriptan benzoat H2O Solubility
42 mg/mL (for free base)
Rizatriptan benzoat State
Solid
Rizatriptan benzoat LogP
2.129
Rizatriptan benzoat Dosage Forms
Tablet; Wafer
Rizatriptan benzoat Indication
For treatment of acute migraine attacks.
Rizatriptan benzoat Pharmacology
Rizatriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Rizatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Rizatriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans.
Rizatriptan benzoat Absorption
Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.
Rizatriptan benzoat side effects and Toxicity
Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting.
Rizatriptan benzoat Patient Information
Migraine or treatment with MAXALT may cause somnolence in some patients. Dizziness has also been reported in some patients receiving MAXALT. Patients should, therefore, evaluate their ability to perform complex tasks during migraine attacks and after administration of MAXALT. Physicians should instruct their patients to read the patient package insert before taking MAXALT.
Rizatriptan benzoat Organisms Affected
Humans and other mammals
